Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutated Lung Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07622706
What this trial is testing

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Who this might be right for
NSCLCEGFR Positive Non-small Cell Lung CancerNeoadjuvant Therapy
Peking University Cancer Hospital & Institute 60
Testing effectiveness (Phase 2)Looking for participantsNCT07744529
What this trial is testing

Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma

Who this might be right for
Leptomeningeal Metastasis From Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 15
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Not applicableUnknownNCT06207292
What this trial is testing

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer

Who this might be right for
NSCLCNSCLC Stage IVOligometastatic Disease+9 more
Radiotherapy Oncology Centre "Santa Maria" Hospital 100
Not applicableStudy completedNCT03059641
What this trial is testing

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

Who this might be right for
Lung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more
Geneplus-Beijing Co. Ltd. 300
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)UnknownNCT04965831
What this trial is testing

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Who this might be right for
Lung Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 40
Testing effectiveness (Phase 2)Study completedNCT04770688
What this trial is testing

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR MutationLocally Advanced Solid TumorMetastatic Cancer+1 more
Shanghai Chest Hospital 25
Large-scale testing (Phase 3)UnknownNCT02929693
What this trial is testing

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Who this might be right for
Cancer
Shanghai University of Traditional Chinese Medicine 198
Testing effectiveness (Phase 2)UnknownNCT02737774
What this trial is testing

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Who this might be right for
Lung Adenocarcinoma
Henan Cancer Hospital 60
Testing effectiveness (Phase 2)Study completedNCT04201756
What this trial is testing

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Who this might be right for
Lung Adenocarcinoma Stage IIIEGFR Gene Mutation
Shanghai Pulmonary Hospital, Shanghai, China 47
Testing effectiveness (Phase 2)Looking for participantsNCT06296745
What this trial is testing

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Who this might be right for
Leptomeningeal Metastasis
Guangzhou Medical University 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06951399
What this trial is testing

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IV Without EGFR/ALK MutationNSCLC Adenocarcinoma
Rabin Medical Center 30
Early research (Phase 1)Active Not RecruitingNCT03993873
What this trial is testing

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Turning Point Therapeutics, Inc. 95
Testing effectiveness (Phase 2)UnknownNCT01131429
What this trial is testing

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Neoplasms, LungCarcinoma, Non-Small Cell LungDrug Therapy+1 more
Chinese PLA General Hospital 60
Testing effectiveness (Phase 2)UnknownNCT02036359
What this trial is testing

Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)
National Taiwan University Hospital 76
Not applicableStudy completedNCT01525199
What this trial is testing

Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

Who this might be right for
Stage IIIB/IVNon-Small Cell Lung Cancer
AstraZeneca 450
Not applicableEnrolling By InvitationNCT06730477
What this trial is testing

Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma

Who this might be right for
Lung AdenocarcinomaEGFR Activating Mutation
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 500
Testing effectiveness (Phase 2)Study completedNCT02759835
What this trial is testing

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Who this might be right for
Lung AdenocarcinomaLung Neoplasms
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05132985
What this trial is testing

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

Who this might be right for
NSCLCEGF-R Positive Non-Small Cell Lung Cancer
Liaoning Cancer Hospital & Institute 45
Next Page